Amgen's KRAS-blocking drug shows minimal effect in colon cancer

Amgen's KRAS-blocking drug shows minimal effect in colon cancer

STAT Plus: Amgen’s KRAS-blocking drug shows minimal effect in colon cancer patients

By ADAM FEUERSTEIN

ANNIE CAVANAGH/WELLCOME

The drug, known as AMG510, has generated significant interest since the release of data showing its potential to shrink tumors in lung cancer patients.

READ MORE